Abstract
Primary intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality rates. In the thrombolytic era, the attention has bee driven on the first hours of onset, when the hematoma is still growing. Intervention with ultra-early hemostatic therapy might arrest ongoing bleeding. Even if recombinant activated factor VII administered within 4 h of symptom onset did not improve outcome in a recent phase 3 trial, it reduced hematoma growth. Therefore, the rational for ultra-early hemostatic therapy it is still valid and another trial on hemostatic treatment is warranted.
| Original language | English |
|---|---|
| Journal | Neurological Sciences |
| Volume | 29 |
| Issue number | SUPPL. 2 |
| DOIs | |
| Publication status | Published - Sep 2008 |
Fingerprint
Keywords
- Hemostatic treatment
- Primary intracerebral hemorrhage
- Randomized controlled trial
- Recombinant activated factor VII
- Tranexamic acid
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Dermatology
Cite this
Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage. / Ciccone, Alfonso; Pozzi, Mario; Motto, Cristina; Tiraboschi, Pietro; Sterzi, Roberto.
In: Neurological Sciences, Vol. 29, No. SUPPL. 2, 09.2008.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage
AU - Ciccone, Alfonso
AU - Pozzi, Mario
AU - Motto, Cristina
AU - Tiraboschi, Pietro
AU - Sterzi, Roberto
PY - 2008/9
Y1 - 2008/9
N2 - Primary intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality rates. In the thrombolytic era, the attention has bee driven on the first hours of onset, when the hematoma is still growing. Intervention with ultra-early hemostatic therapy might arrest ongoing bleeding. Even if recombinant activated factor VII administered within 4 h of symptom onset did not improve outcome in a recent phase 3 trial, it reduced hematoma growth. Therefore, the rational for ultra-early hemostatic therapy it is still valid and another trial on hemostatic treatment is warranted.
AB - Primary intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality rates. In the thrombolytic era, the attention has bee driven on the first hours of onset, when the hematoma is still growing. Intervention with ultra-early hemostatic therapy might arrest ongoing bleeding. Even if recombinant activated factor VII administered within 4 h of symptom onset did not improve outcome in a recent phase 3 trial, it reduced hematoma growth. Therefore, the rational for ultra-early hemostatic therapy it is still valid and another trial on hemostatic treatment is warranted.
KW - Hemostatic treatment
KW - Primary intracerebral hemorrhage
KW - Randomized controlled trial
KW - Recombinant activated factor VII
KW - Tranexamic acid
UR - http://www.scopus.com/inward/record.url?scp=53649091448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=53649091448&partnerID=8YFLogxK
U2 - 10.1007/s10072-008-0955-9
DO - 10.1007/s10072-008-0955-9
M3 - Article
VL - 29
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
IS - SUPPL. 2
ER -